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Abstract
Voriconazole is the mainstay of treatment for invasive aspergillosis in immunocompromised pediatric pa-
tients. Although Therapeutic DrugMonitoring (TDM) of voriconazole is recommended, it remains unknown if
TDM-based dose adaptations result in target attainment. Patients<19 years from two pediatric hematologic-
oncology wards were retrospectively identified based on unexplained high voriconazole trough concentra-
tions (Cmin > 6 mg/l). Patient demographics, clinical characteristics, treatment, voriconazole dosing infor-
mation, voriconazole Cmin before and after adjustment based on TDM were obtained. Twenty-one patients,
median (range) age 7.0 (1.2–18.5) years, were identified in two centers. First Cmin (3.1 mg/l [0.1–13.5]) was
obtained after 3 days (1–27) of treatment. The median of all Cmin (n = 485, median 11 per patient) was
2.16 mg/l (0.0 (undetectable)–28.0), with 24.1% of Cmin < 1 mg/l, 48.9% 1–4 mg/l, 9.3% 4–6 mg/l, and 17.7%
> 6 mg/l. Intrapatient variability was large (94.1% for IV, 88.5% for PO). Dose increases at Cmin < 1 mg/l
resulted in an increased Cmin in 76.4%, with 60% between 1 and 4 mg/l. Dose decreases at Cmin > 6 mg/l
resulted in a decreased Cmin in 80%, with 51% between 1 and 4 mg/l. Overall, in 45% of the cases (33 out
of 55 and 12 out of 45) therapeutic targets were attained after dose adjustment. Fifty-five percent of initial
Cmin was outside the therapeutic target of 1–4 mg/l, with multiple dose adaptations required to achieve ther-
apeutic concentrations. Only 60% and 51% of dose adaptations following sub- and supra-therapeutic Cmin,
respectively, did result in target attainment. Intensive and continuous TDM of voriconazole is a prerequisite
for ensuring adequate exposure in pediatric patients.
Key words: voriconazole, therapeutic drug monitoring, pediatrics, azoles, pharmacokinetics.
Introduction
Voriconazole is a broad-spectrum triazole antifungal agent that
has emerged as the preferred treatment of invasive aspergillosis
in both children (≥2 years of age) and adults.1,2
Increased voriconazole exposure has been associated with im-
proved treatment outcome in adults, with suggested provisional
cutoff points for voriconazole trough plasma concentrations
(Cmin) of 1–6 mg/l.3–6 An exposure-response relationship was
also established for pediatric patients, in which a voriconazole
C© The Author(s) 2019. Published by Oxford University Press on behalf of The International Society for Human and Animal
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Cmin > 1 mg/l was associated with improved outcomes.7–11
Based on the relationship between voriconazole exposure and
efficacy and the high inter- and intra-patient variability in pedi-
atric patients,12–15 the importance of voriconazole therapeutic
drug monitoring (TDM) in pediatric patients has been acknowl-
edged.1,2,16,17 Although TDM-based dose adjustments are per-
formed to optimize plasma concentrations, it remains unclear
if these dose adaptations in pediatric patients correspond with
target attainment.
We conducted a retrospective analysis in a cohort of pediatric
oncology patients (both leukemia as well as lymphoma) with
difficult to manage voriconazole concentrations and assessed the
result of TDM-based dose adaptations on target attainment.
Methods
Study design and patients
This retrospective analysis was carried out in the pediatric
hematology-oncology wards of two university hospitals in the
Netherlands (Radboud university medical center, Nijmegen and
Sophia Children’s Hospital, Erasmus Medical Center, Rotter-
dam). From August 2007 to May 2014, the results from rou-
tinely performed TDM of voriconazole in both hospitalized and
ambulant pediatric patients were evaluated. Patients < 19 years
who received voriconazole orally (PO) or intravenously (IV)were
included if more than one voriconazole Cmin was determined, of
which at least one concentration was >6 mg/l during treatment.
Due to the retrospective nature of the study, written informed
consent was deemed not necessary.
Data collection
Data were collected from the patients’ medical records and
included patient demographics (e.g., age, sex, body weight),
voriconazole treatment data (e.g., route of administration, treat-
ment duration, total daily dose, dose adjustments) and TDM
data (e.g., plasma trough concentrations [Cmin], number of sam-
ples per patient, number of sub- and supra-therapeutic Cmin).
Concomitant medications with or without a known or suspected
interaction with voriconazole exposure were reported.
Voriconazole dosing and dose adjustments
Initial dosing and administration of voriconazole was according
to the Summary of Product Characteristics (SmPC) of voricona-
zole but could be increased or decreased based on clinical in-
dications and TDM results. End of treatment was defined by
successful clinical response, or by discontinuation due to a lack
of clinical response, or adverse events. Consistent with institu-
tion guidelines during the study period, adequate voriconazole
exposure was defined as Cmin between 1 and 4 mg/l. If the pa-
tient showed no signs of hepatotoxicity (i.e., liver function tests
no more than three times the upper limit of normal), Cmin up to
6 mg/l were accepted. The 4 mg/l target concentration to prevent
hepatotoxicity has been established in Asian patients particu-
larly.18,19 In white people this relation has not been established
with a clear cutoff value. Rather, an increase in drugs concen-
tration, results in an increased chance of encountering hepato-
toxicity.20 In case of sanctuary infection sites or disseminated
disease, the lower threshold was set to 2 mg/l (i.e., 2–4 mg/l or
2–6 mg/l). Target concentrations remain subject to debate but
our target concentrations are in line with the recently published
ESCMID guideline2 and the ECIL guideline (available online via
www.ecil-leukaemia.com).
In case of a sub- or supra-therapeutic voriconazole Cmin
(< 1 or > 6 mg/l), dose adjustments, assuming near-linear
pharmacokinetics in children,14 to reach adequate Cmin were
subsequently made. A follow-up sample within 1 week was rec-
ommended. Dosing frequency was initially two times daily but
could be increased to three times daily in an attempt to reach
adequate voriconazole exposure.
Therapeutic Drug Monitoring
TDM was performed as standard of care, but frequency of sam-
pling was dependent on individual decisions made for each pa-
tient. First, TDM sample was recommended at steady state con-
centrations of the drug, which is at least 2 days after initiation of
voriconazole therapy or following dose adaptations. Only blood
samples withdrawn within a 1-hour period prior to the next
dose were included in the analysis to ascertain a trough concen-
tration. Decisions on dose adaptations were made by experts in
the field with knowledge on PK of voriconazole taking in mind
the clinical condition of the patient.
Analytical assay
Voriconazole plasma concentrations were measured twice
weekly using an in-house, validated ultra-performance liquid
chromatography (HPLC) method with either a fluorescence or
MSMS detection method (Waters).
Data analysis
A Spearman rank-order correlation was run to determine the
relationship between voriconazole dose andCmin using SPSS 20.0
(SPSS Inc., Chicago, IL, USA). A P-value of<.05 was considered
statistically significant. Intra-patient variability of voriconazole
Cmin was analyzed in patients who had at least three voriconazole
Cmin at similar doses and formulations.
Results
Patients
Twenty-one patients (8 male, 13 female) were eligible for anal-
ysis. Median (range) age at first dose was 7.0 years (1.2–18.5
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years), of which 3 patients (14.3%) were <2 years, 11 (52.4%)
between 2 and 12 years, and 7 (33.3%) between 12 and 19
years. Median (range) weight and body mass index were 21.9 kg
(9.5–65) and 17.7 kg/m2 (14–25.4), respectively (Table 1).
Voriconazole therapy
Patients received voriconazole therapy for a median (range) of
118 days (17–866; Table 1). The median total daily dose per kg
(range) was 23.1 mg/kg (6.1–109.6). Initial voriconazole admin-
istration was IV in 15 (71.4%) and PO in 6 (28.6%) of patients.
Five patients received voriconazole orally only, 2 only IV, and
14 received a combination of both. In four patients voriconazole
was given TID at some time as part of their management strat-
egy for a median (range) of 60 days (6–397) with a median total
daily dose of 34.4 mg/kg (13.6–109.6). Median intra-individual
variability of voriconazole dose was 94.1% during IV therapy
(dose range: 12.2–16.0 mg/kg/day) and 88.5% during PO ther-
apy (dose range: 10.5–44.1 mg/kg/day).
Therapeutic drug monitoring – initial Cmin
The first measurement of voriconazole Cmin was performed at a
median (range) of 3 days (1–27) after start of treatment, with a
median (IQR) Cmin of 3.1 mg/l (1.34-7.0; Table 1). Upon first
measurement, 11 out of 21 (52.4%) patients reached a Cmin
between 1 and 6 mg/l (7 of these patients received voriconazole
IV, 4 PO). Of the remaining 10 patients who had a voriconazole
concentration <1 mg/l or >6 mg/l at first measurement, five
out of nine patients (55.5%) required only 1 dose adaptation to
achieve a Cmin between 1 and 6 mg/l. Target concentrations in
these nine patients were attained after a median (range) of 15
days (8–123). One patient was unable to achieve target values
during the entire length of voriconazole therapy despite TDM-
based dose adaptations. After the first suboptimal Cmin, TDM-
based dose adaptations were performed within a median of 2
days. A very weak positive correlation between voriconazole
dose and initial Cmin was calculated, which was not statistically
significant (r2 = 0.05, P = .82).
Therapeutic drug monitoring – all Cmin
In total, 485 samples were obtained with a median (range) con-
centration of 2.16 mg/l (undetectable -28; Table 1). Four con-
centrations (0.8%) were reported as below the lower limit of
quantification. A median (range) of 11 samples (2–109) were
drawn per patient, of which 117 (24.1%) were <1 mg/l, 237
(48.9%) between 1 and -4 mg/l, 45 (9.3%) between 4 and 6 mg/l
and 86 (17.7%) >6 mg/l. An overview of all Cmin per patient is
shown in Figure 1. There was no significant correlation between
voriconazole dose and all Cmin, (rs (485)= 0.02, P= .59). A Cmin
<1 mg/l was most frequently encountered in patients >12 years
receiving voriconazole IV, whereas patients 2–12 years suffered
most frequently from Cmin > 6 mg/l (Fig. 2).
Voriconazole dose adaptations
A total of 108 dose increases and 135 dose decreases were made,
of which 50.9% when Cmin < 1, and 33.3% Cmin > 6 (see
Table 1). Out of a 117 cases with a Cmin <1mg/l prompted a dose
increase in 47.0% (n = 55) of occurrences, which resulted in an
increased Cmin at follow-up sampling in 76.4% (n= 42) of cases.
In 60% (n = 33) of dose increases following a concentration of
<1 mg/l, this led to a therapeutic Cmin between 1 and 4 mg/l
(median 1.7 mg/l). In these 33 cases, the total daily dose was
increased from a median of 18.3 mg/kg/day to 22.7 mg/kg/day
(24.0%).
Out of 86 cases with a Cmin of>6mg/l (median 8.29mg/l) this
prompted a dose decrease in 52.3% (n = 45) of cases, of which
80.0% (n= 36) resulted in a subsequent lower Cmin at follow-up
sampling. These dose decreases resulted in a Cmin of <6 mg/l in
51.1% (n = 23) of cases and even led to concentrations between
1 and 4 mg/l (median 2.3 mg/l) in 26.7% (n = 12). In these
12 cases, the total daily dose was decreased from a median of
23.5 mg/kg/day to 16.8 mg/kg/day (39.9%).
Discussion
Here we present our experience with voriconazole TDM in a co-
hort of 21 pediatric patients with difficult to control voriconazole
Cmin, characterized by at least one Cmin > 6 mg/l, enabling us to
assess the result of TDM-based dose adaptations on voriconazole
target attainment.
Overall, 18.5% of all doses adjustments made, based on
TDM, resulted in target concentrations (1–4 mg/l). The vast ma-
jority (95.2%) of the patients in our study were able to achieve at
least one therapeutic concentration (1–4 mg/l) after TDM-based
dose adjustments. This is in a similar range of the reported value
of 80% in a study from Bartelink et al., although voriconazole
target values of 1–5 mg/l were used in this study.21
Of the total number of 485 voriconazole Cmin, 24.1% was
<1 mg/l, which is correlated with increased likelihood of treat-
ment failure in children.7-9 In case of such a subtherapeutic Cmin,
voriconazole dose was increased in 47.0% of cases. Accordingly,
60% of dose increases resulted in the desired therapeutic Cmin
of 1–4 mg/l, with a median dose increase from 18.3 mg/kg/day
to 22.7 mg/kg/day. Previous studies have reported that dose ad-
justments to median doses of 20–40 mg/kg/day were required to
obtain therapeutic plasma concentrations of >1 mg/l.9,10,22 In
addition, 17.7% of the total number of voriconazole Cmin were
>6 mg/l, which is regarded as a cutoff concentration for hep-
atotoxicity in adults (23), although no clear correlation is seen
in pediatric patients.7,23,24 At these supratherapeutic concentra-
tions, voriconazole dose was lowered in 52.3% of cases, result-
ing in a Cmin between the target range of 1 and 4 mg/l in 26.7%
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Table 1. Baseline characteristics (n = 21).
Demographics
Sex
Male (n [%]) 8 (38.1)
Female (n [%]) 13 (61.9)
Median age at first VCZa dose (yr [range]) 7.0 (1.2–18.5)
Age class (yr)
0–<2 (n [%]) 3 (14.3)
2–<12 (n [%]) 11 (52.4)
12–18 (n [%]) 7 (33.3)
Race
White (n [%]) 18 (85.7)
Black (n [%]) 2 (9.5)
Asian (n [%]) 1 (4.8)
Median weight (kg [range]) 21.9 (9.5–65)
Median BMI (kg/m2 [range]) 17.7 (14–25.4)
Voriconazole therapy
Median days of VCZa therapy (n [range]) 118 (17–866)
Intravenous administrations (%) 12.5
Oral administrations (%) 87.5
Median total daily dose (mg [range]) 400 (120–2400)
Median total daily dose per kg (mg/kg [range]) 23.1 (6.1–109.6)
Patients on temporarily TIDb dosing (n [%]) 4 (19)
Median days of TIDb dosing (n range) 60 (6–397)
Median total daily dose during TID dosing (mg/kg [range]) 34.4 (13.6–109.6)
TID dosing administrations (% of total) 11.1
Therapeutic drug monitoring
Median days until first measurement of VCZa Cminc (n [range]) 3 (0–27)
Median plasma concentration of first Cminc (mg/l [IQRd]) 3.1 (1.34–7.0)
Initial Cmin adequate (% of all patients)e 11 (52.4)
Intravenous administration (%) 7 (63.6)
Oral administration (%) 4 (36.4)
Initial Cmin below therapeutic range (% of all patients) 4 (19)
Intravenous administration (%) 3 (75)
Oral administration (%) 1 (25)
Initial Cmin above therapeutic range (% of all patients) 6 (28.6)
Intravenous administration (%) 4 (66.7)
Oral administration (%) 2 (33.3)
Total Cmin 485
<1 mg/l (n [%]) 117 (24.1)
1–4 mg/l (n [%]) 237 (48.9)
4–6 mg/l (n [%]) 45 (9.3)
>6 mg/l (n [%]) 86 (17.7)
Median concentration of all Cmin (mg/l; range) 2.16 (0–28.0)
Dose adaptations
Dose adaptations (n [%]) 243 (50.1)
Dose increases (total) 108
Dose increase at Cmin < 1 mg/l (n [%]) 55 (47)
Resulted in increase in Cmin 42 (76.4)
Resulted in Cmin 1–4 mg/l 33 (60)
Dose decrease (total) 135
Dose decrease at Cmin > 6 mg/l 45 (33.3)
Resulted in decrease in Cmin 36 (80.0)
Resulted in Cmin < 6 mg/l 23 (51.1)
Resulted in Cmin 1–4 mg/l 12 (26.7)
aVCZ = voriconazole. bTID = three times per day. cCmin = trough concentration. dIQR = Interquartile range. eAdequate therapeutic range of voriconazole Cmin is considered
to be between 1 and 4 mg/l (1–6 if adequate liver function tests). Subtherapeutic Cmin at <1 mg/l, supratherapeutic Cmin at >6 mg/l.
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Figure 1. Overview of all voriconazole trough concentrations at varying doses (n = 485) in 21 patients.
of cases (decreasing the median dose from 23.5 mg/kg/day to
16.8 mg/kg/day).
Age is one of the most important factors influencing voricona-
zole plasma exposure, as voriconazole clearance has been shown
to be much higher in children under the age of 12, and oral
bioavailability of voriconazole is lower in children (65%), com-
pared to adults (96%).14,25 As a result, several studies reported
similar voriconazole exposure in children (<12 years) compared
to adults with IV doses of 7–9 mg/kg BID.13,14,25 This prompted
higher dosing regimens in children compared to adults. Although
voriconazole has been reported to display near-linear pharma-
cokinetics in children receiving multiple doses of 3 mg/kg and
4 mg/kg BID IV15 (i.e., doses that have been found effective
in clinical trials with adults), increasing evidence suggests satu-
rated (nonlinear) pharmacokinetic behavior is observed in chil-
dren receiving doses higher than 7 mg/kg BID. We found no
predictable relationship between dose and Cmin (Fig. 1,2), and
it remains unclear from current literature if such a relation-
ship exists. Given the high maintenance doses in our study
(median 23.1 mg/kg/day), this could explain the absence of a
dose/concentration relationship. Another explanation could be
found in the high intra-subject variability in voriconazole Cmin
both after IV and PO dosing (Fig. 1), which is consistent with
other pediatric studies.12–14,25
Due to the retrospective nature of this study, laboratory data
on the majority of our patients were limited and often obtained
only on the day of voriconazole TDM. In addition, markers for
hepatic function were not always investigated in parallel. It was
therefore not possible to draw any conclusions on the yet un-
clear relationship between voriconazole Cmin and hepatotoxicity
in pediatric patients. Because the focus of our study on the rela-
tionship between dose adjustments and target attainment, we did
not monitor for voriconazole-related adverse events (e.g., neuro-
logical adverse events, phototoxic skin reactions, and potentially
proarrhythmic conditions) in relation to dose or exposure.
Despite rapid dose adaptations after the first subtherapeutic
Cmin in our study (median of 2 days), a median of 15 days was
required to obtain an adequate Cmin, increasing the risk of inade-
quately treated fungal infections and unfavourable outcome. Of
all dose adaptations following both sub –and supratherapeutic
Cmin, only 45% resulted in a therapeutic Cmin between 1 and 4
mg/l at the following concentration measurement. If we would
stretch the therapeutic targets to 1–6 mg/l (assuming all Cmin
between 4 and 6 mg/l were acceptable based on adequate liver
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Figure 2. Voriconazole Cmin distribution (%) per formulation per age group. Cmin: trough concentration. IV: intravenous. PO: Oral.
function tests), 56% of dose adaptations would result in target
attainment.
Dose adaptations were done by experts with expertise in the
field of antifungal pharmacology but without a nomogram. For
purposes of personalized dosing, there is an urgent need to imple-
ment advanced pharmacometric models with “clinician-proof”
software, that can take into account all important determinants
for treatment response. Nowadays, model-informed precision
dosing (MIPD) can be deployed as a technique to forecast dos-
ing in the individual. Programs such as InsightRx, DoseMe and
Best Dose fulfil this need and are being tested in the clinic. To
take advantage of this approach, solid pharmacokinetic models
must be available to be used in MIPD. Here we can still gain
knowledge for this specific drug and the current population as
the unexplained inter-individual variability in published models
remains very large. Before implementation in routine patient
management, these models must be prospectively validated to
demonstrate its value. In addition, the software must comply
to relevant legislation (e.g., CE label in Europe) when deployed
outside of a research scope. Nevertheless, this is the way forward
taking advantage of a platform for individualized treatment with
visual feedback.
Given the difficulty of target attainment despite dose adap-
tations, together with the prior observed relationship between
voriconazole exposure and efficacy and adverse events and the
large inter- and intrapatient variability in children, this study
underscores the indispensable need for voriconazole TDM in
severely immunocompromised pediatric patients early in the
course of treatment with multiple follow-up samples during ther-
apy when aiming to optimize treatment outcomes.
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